Detailed diagnostic imaging

Article

Breaking news from the floor of ESCRS

Heidelberg Engineering has been showing off BluePeak laser autofluorescence, a diagnostic imaging modality that the company reports provides a functional map of the RPE-photoreceptor metabolism allowing users to non-invasively view the health of the RPE. The latest addition to this is the new RegionFinder software that the company claims allows users to quantify atrophic areas easily and to reliably monitor changes over time.

BluePeak is available for all SPECTRALIS SD-OCT models as is the new Anterior Segment Module, which is the company claims, bringing a new dimension to anterior segment imaging. The module consists of an add-on lens and software and allows the device to capture simultaneous IR and OCT imaging of the cornea, sclera and chamber angle to provide a detailed 3D view of the anterior chamber. According to the company the dual-angle white-to-white scan provides a perspective of the iris and lens that is not visible with single-angle scans.

Visitors to the booth were also invited to experience the Heidelberg Edge Perimeter. This perimeter technology offers two stimuli in one perimeter: the Flicker-Defined-Form and the Standard Automated Perimetry. According to the company, by combining this with the Heidelberg Retina Tomograph they have created the first visual field device to read in structural information and to conjointly display structural and functional data in the new Structure-Function Map.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.